ValiRx Extends Exclusivity Agreement with TheoremRx
Company Announcements

ValiRx Extends Exclusivity Agreement with TheoremRx

ValiRx plc (GB:VAL) has released an update.

ValiRx PLC has extended its exclusivity agreement with TheoremRx Inc until the end of 2024, in exchange for a 0.5% equity stake. This extension aims to support TheoremRx in securing financing necessary for the sublicensing of ValiRx’s VAL201 cancer therapeutic. Investors are watching closely as the deal remains non-binding and dependent on successful financial arrangements.

For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskValiRx plc Announces Board Changes Amid Strategic Focus
TipRanks UK Auto-Generated NewsdeskValiRx plc to Reveal Future Strategies in CEO Webinar
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App